Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

NCT05805501 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05805501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05805501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 21, 2023
Completion date
October 8, 2026
Enrollment
199 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma